Evidence map›Paper›PMID 30483474›Full record

ArticleFrontiers in oncology2018

Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy.

Sergio González Rubio, Nuria Montero Pastor, Carolina García, Víctor G Almendro-Vedia, Irene Ferrer, Paolo Natale, Luis Paz-Ares, M Pilar Lillo, Iván López-Montero

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sergio González RubioDepartamento de Química Física, Universidad Complutense de Madrid, Madrid, Spain.
Nuria Montero PastorDepartamento de Química Física, Universidad Complutense de Madrid, Madrid, Spain.
Carolina GarcíaDepartamento de Química Física Biológica, Instituto de Química-Física "Rocasolano" (CSIC), Madrid, Spain.
Víctor G Almendro-VediaDepartamento de Química Física, Universidad Complutense de Madrid, Madrid, Spain.
Irene FerrerInstituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.
Paolo NataleDepartamento de Química Física, Universidad Complutense de Madrid, Madrid, Spain.
Luis Paz-AresInstituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.
M Pilar LilloDepartamento de Química Física Biológica, Instituto de Química-Física "Rocasolano" (CSIC), Madrid, Spain.
Iván López-MonteroDepartamento de Química Física, Universidad Complutense de Madrid, Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESInstituto de Química Física Blas Cabrera · ESUniversidad Complutense de Madrid · ESSpanish National Cancer Research Centre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cell mitochondria represent an attractive target for oncological treatment as they have unique hallmarks that differ from their healthy counterparts, as the presence of a stronger membrane potential that can be exploited to specifically accumulate cytotoxic cationic molecules. Here, we explore the selective cytotoxic effect of 10-

Indexed as

cancer therapyFLIMmembrane adhesionmitochondrial targetingNAONSCLC cellsphasor analysis

Identifiers

PMID30483474
PMCPMC6242888
OpenAlexW2901830040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.